Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms

Bibliography

• Yip KW, Reed JC, Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27:6398-406
   PubMed Web of Science ®Google Scholar
• Kim I, Xu W, Reed JC, Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities.. Nat Rev Drug Discov 2008;7:1013-30
   PubMed Web of Science ®Google Scholar
• Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A, Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59
   PubMed Web of Science ®Google Scholar
• Nuessler V, Stotzer O, Gullis E, Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 1999;13:1864-72
   PubMed Web of Science ®Google Scholar
• Andreeff M, Jiang S, Zhang X, Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-92
   PubMed Web of Science ®Google Scholar
• Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27(Suppl 1):S149-57
   PubMed Web of Science ®Google Scholar
• Khaw SL, Huang DC, Roberts AW. BH3-mimetics: the solution to chemoresistance? Leuk Lymphoma 2009;50:1069-72
   PubMed Web of Science ®Google Scholar
• Ketley NJ, Allen PD, Kelsey SM, Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia 2000;14:620-8
   PubMed Web of Science ®Google Scholar
• Stahnke K, Mohr A, Liu J, Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis. Apoptosis 2004;9:457-65
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19
   PubMed Web of Science ®Google Scholar
• Merino R, Ding L, Veis DJ, Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994;13:683-91
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010;430:199-205
   PubMed Web of Science ®Google Scholar
• Shore GC, Viallet J. Modulating the Bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology (Am Soc Hematol Educ Program) 2005;2005:226-30
   Google Scholar
• Nguyen M, Marcellus RC, Roulston A, Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104:19512-17
   PubMed Web of Science ®Google Scholar
• Pepper C, Hoy T, Bentley DP, Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935-8
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Lopez-Guerra M, BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008;22:1712-20
   PubMed Web of Science ®Google Scholar
• Konopleva M, Watt J, Contractor R, Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008;68:3413-20
   PubMed Web of Science ®Google Scholar
• Koh GS, Jiang N, Dong DF, BH3-Mimetics, ABT-737 and obatoclax, work synergistically to induce cell death in leukemic cell lines. ASH Annual Meeting Abstracts. Blood 2010;116:1850
   Google Scholar
• Wei Y, Kadia T, Tong W, The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 2010;16:3923-32
   PubMed Web of Science ®Google Scholar
• Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 2010;1:e76
   PubMed Web of Science ®Google Scholar
• Urtishak KA, Wang LS, Harvey R, Infant acute lymphoblastic leukemias are pan-sensitive to obatoclax across molecular/cytogenetic subtypes, especially MLL-ENL, and gene expression profiles determine obatoclax IC50: a report on the Children's Oncology Group (COG) P9407 trial. ASH Annual Meeting Abstracts. Blood 2010;116:2757
   Google Scholar
• Perez-Galan P, Roue G, Villamor N, The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-9
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F, Tsio PC, Campagna R, Obatoclax and bortezomib therapy results in disruption of the p53-mediated apoptosis/autophagy pathway and is associated with potent synergistic anti-tumor activity against rituximab-chemotherapy-sensitive and -resistant B-Cell lymphoma. ASH Annual Meeting Abstracts. Blood 2009;114:288
   Google Scholar
• Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle 2011;10:2792-805
   PubMed Web of Science ®Google Scholar
• Brem EA, Thudium K, Khubchandani S, Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 2011;153:599-611
   PubMed Web of Science ®Google Scholar
• Jona A, Khaskhely N, Buglio D, The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011;39:1007-17
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Rauw J, Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-8
   PubMed Web of Science ®Google Scholar
• Huang S, Okumura K, Sinicrope FA, BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 2009;15:150-9
   PubMed Web of Science ®Google Scholar
• Smoot RL, Blechacz BR, Werneburg NW, A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 2010;70:1960-9
   PubMed Web of Science ®Google Scholar
• Pan J, Cheng C, Verstovsek S, The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 2010;293:167-74
   PubMed Web of Science ®Google Scholar
• Jiang CC, Wroblewski D, Yang F, Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia (New York) 2009;11:945-55
   PubMed Web of Science ®Google Scholar
• Schimmer AD, O'Brien S, Kantarjian H, A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295-301
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Claxton DF, Crump M, Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299-305
   PubMed Web of Science ®Google Scholar
• Hwang JJ, Kuruvilla J, Mendelson D, Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010;16:4038-45
   PubMed Web of Science ®Google Scholar
• Goy A, Ford P, Feldman T, A Phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. ASH Annual Meeting Abstracts. Blood 2007;110:2569
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kantarjian H, Schimmer A, Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leukoc 2010;10:285-9
   PubMed Web of Science ®Google Scholar
• A. Chiappori MTSMMMJSLBRSQSCHJRDSSMSB. Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC) [abstract No: e13531]. 2011
   Google Scholar
• Paik PK, Rudin CM, Brown A, A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010;66:1079-85
   PubMed Web of Science ®Google Scholar
• Roberts AW, Brown J, Seymour JF, An ongoing phase 1 study of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2008;112:3177
   Google Scholar
• Wilson WH, O'Connor O, Czuczman MS, Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies. ASH Annual Meeting Abstracts. Blood 2008;112:2108
   Google Scholar
• Roberts AW, Seymour JF, Brown JR, An ongoing phase 1/2a study of ABT-263; Pharmacokinetics (PK), safety and anti-tumor activity in patients (pts) with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2009;114:883
   Google Scholar
• Balakrishnan K, Burger JA, Wierda WG, AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009;113:149-53
   PubMed Web of Science ®Google Scholar
• Liu G, Kelly WK, Wilding G, An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009;15:3172-6
   PubMed Web of Science ®Google Scholar
• McGregor N, Patel L, Craig M, AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. J Cell Biochem 2010;110:1187-94
   PubMed Web of Science ®Google Scholar
• Deng J, Carlson N, Takeyama K, BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-85
   PubMed Web of Science ®Google Scholar
• Brem EA, Thudium K, Khubchandani S, Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 2011;153:599-611
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Bhagat G, The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906-16
   PubMed Web of Science ®Google Scholar